Skip to main content

Table 1 Characteristics of subjects entered into the Astra Zeneca sponsored clinical study D1330N00013 whose blood samples where utilised in the present study

From: Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells

Patient Age (Median) Performance status (Who) Stage Grade (Gleason) Baseline PSA (Median, ng/ml)
Group I 71 Normal-Restricted Activity Localised Intermediate (5–7) 7.0
Group II 74 Normal-Restricted Activity Locally Advanced/ Metastatic High (8–10) 23.2